Journal of Alzheimers Disease & Parkinsonism最新文献_第6页

Identification of Serum Anti-GADD34 Antibody as a Common Marker ofDiabetes Mellitus and Parkinson Disease 血清抗gadd34抗体作为糖尿病和帕金森病共同标志物的鉴定

Journal of Alzheimers Disease & Parkinsonism Pub Date : 2017-08-03 DOI: 10.4172/2161-0460.1000358

K. Sugimoto, Go Tomiyoshi, M. Mori, S. Kuwabara, S. Hirano, S. Sawai, M. Beppu, M. Muto, A. Uzawa, K. Kitamura, M. Takemoto, A. Hattori, Masashi Yamamoto, Kazuki Kobayashi, H. Kawamura, Ryoichi Ishibashi, K. Yokote, S. Mine, T. Machida, E. Kobayashi, Y. Yoshida, T. Matsutani, Y. Iwadate, Yoshio Kobayashi, Rika Nakamura, Natsuko Shinmen, Hideyuki Kuroda, Hao Wang, Xiao-meng Zhang, Takaki Hiwa

{"title":"Identification of Serum Anti-GADD34 Antibody as a Common Marker ofDiabetes Mellitus and Parkinson Disease","authors":"K. Sugimoto, Go Tomiyoshi, M. Mori, S. Kuwabara, S. Hirano, S. Sawai, M. Beppu, M. Muto, A. Uzawa, K. Kitamura, M. Takemoto, A. Hattori, Masashi Yamamoto, Kazuki Kobayashi, H. Kawamura, Ryoichi Ishibashi, K. Yokote, S. Mine, T. Machida, E. Kobayashi, Y. Yoshida, T. Matsutani, Y. Iwadate, Yoshio Kobayashi, Rika Nakamura, Natsuko Shinmen, Hideyuki Kuroda, Hao Wang, Xiao-meng Zhang, Takaki Hiwa","doi":"10.4172/2161-0460.1000358","DOIUrl":"https://doi.org/10.4172/2161-0460.1000358","url":null,"abstract":"Background: Growth arrest and DNA-damage-inducible gene 34 (GADD34) has been identified as an antigen by serological identification of antigens by cDNA expression cloning (SEREX) using the sera of patients with atherosclerosis. It is possible that GADD34 is associated with atherosclerosis-related diseases such as diabetes mellitus (DM), acute-phase cerebral infarction (aCI), cardiovascular disease (CVD), and chronic kidney disease (CKD) as well as endoplasmic reticulum stress-related Parkinson disease (PD). Methods: GADD34 protein was bacterially expressed and purified. Amplified luminescent proximity homogeneous assay (AlphaLISA) was used to evaluate serum antibody levels against GADD34 protein in serum samples. Results: AlphaLISA revealed significantly higher serum antibody levels against GADD34 protein in patients with DM, aCI and CVD than those in healthy donors (HDs). The difference in levels between DM and HD was more prominent than that between aCI or CVD and HDs. The anti-GADD34 antibody levels were also elevated in the sera of diabetic CKD patients; thus, the anti-GADD34 antibodies appeared to be the most associated with DM, which is also a risk factor of PD. Anti-GADD34 antibody levels were also higher in patients with PD but not in those with amyotrophic lateral sclerosis as compared with those in HDs. Conclusion: Anti-GADD34 antibody may be a useful diagnostic tool for DM and PD. GADD34 may account for the pathophysiological relationship between DM and PD.","PeriodicalId":15012,"journal":{"name":"Journal of Alzheimers Disease & Parkinsonism","volume":"1 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2017-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89714835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Comparative Analysis of Nasal Therapy with Soluble and Liposomal Forms of Curcumin on Rats with AlzheimerÃ¢Â€Â™s Disease Model 可溶性和脂质体形式姜黄素鼻腔治疗AlzheimerÃ¢Â€Â™疾病模型大鼠的比较分析

Journal of Alzheimers Disease & Parkinsonism Pub Date : 2017-08-01 DOI: 10.4172/2161-0460.1000357

Sokolik Vv, Berchenko Og, Shul'ga Sm

引用次数: 14

Efficacy of Incobotulinumtoxin Type A (Xeomin ® ) in the Management of Sialorrhea in Neurodegenerative Diseases A型肉毒杆菌毒素(Xeomin®)治疗神经退行性疾病患者唾液的疗效

Journal of Alzheimers Disease & Parkinsonism Pub Date : 2017-07-31 DOI: 10.4172/2161-0460.1000356

R. Marvulli, L. Mastromauro, G. Devenuto, M. Napolitano, Falcicchio Ml, G. Gallo, E. Schivardi, P. Fiore, M. Megna, G. Ianieri

{"title":"Efficacy of Incobotulinumtoxin Type A (Xeomin ® ) in the Management of Sialorrhea in Neurodegenerative Diseases","authors":"R. Marvulli, L. Mastromauro, G. Devenuto, M. Napolitano, Falcicchio Ml, G. Gallo, E. Schivardi, P. Fiore, M. Megna, G. Ianieri","doi":"10.4172/2161-0460.1000356","DOIUrl":"https://doi.org/10.4172/2161-0460.1000356","url":null,"abstract":"Introduction: One of the symptoms of two very common and serious neurodegenerative diseases such as Amyotrophic Lateral Sclerosis and Parkinson’s disease is sialorrhea. It can cause macerations and fissures in perioral region, halitosis, dysarthria, aspiration penumonia, asphyxiation and patient’s awkwardness. Management can be conservative (medical therapy using anticholinergic drugs) or more invasive (surgery with excision of salivary glands, duct’s ligation and transposition). Botulinum toxin A is a non invasive and poor side effects alternative. Aim of this study is to examine therapeutic resources for sialorrhea in Amyotrophic Lateral Sclerosis and Parkinson’s disease, by objective and subjective evaluation. Materials and methods: 20 patients with sialorrhea caused by Parkinson’s disease (10 patients) and ALS (10 patients). Incobotulinum toxin A (XEOMIN®, Merz Pharma), was injected under ultrasound guide in the submandibular and parotid glands. At t0 (pre-injection), t1 (30 days later), t2 (90 days later), t3 (120 days later), t4 (150 days later) and t5 (180 days later, only in PD group) we submitted Visual Analogue Scale (VAS) to estimated the level of salivation (1 was the best state and 10 the worst state), Gauze’s test to perform the weighed of the gauze after 1 minute and Sugar lump’s test to evaluate time necessary for melting. Results: In Parkinson’s and ALS group gauze’s test, sugar lump’s test and VAS improved until 6 months (PD group) and 5 months (ALS group), with p<0,05. Conclusion: This study concludes that therapeutic resource with Botulinum toxin A is an efficient treatment option for sialorrhea in patients with ALS and PD.","PeriodicalId":15012,"journal":{"name":"Journal of Alzheimers Disease & Parkinsonism","volume":"9 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2017-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75060023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Botulinum Toxin Type A and Physiokinesiterapy in the Treatment of PisaSyndrome A型肉毒毒素与生理运动疗法治疗pisynsyndrome

Journal of Alzheimers Disease & Parkinsonism Pub Date : 2017-07-27 DOI: 10.4172/2161-0460.1000354

R. Marvulli, L. Mastromauro, Falcicchio Ml, Gallo Ga, M. Napolitano, E. Schivardi, P. Fiore, M. Megna, G. Ianieri

{"title":"Botulinum Toxin Type A and Physiokinesiterapy in the Treatment of PisaSyndrome","authors":"R. Marvulli, L. Mastromauro, Falcicchio Ml, Gallo Ga, M. Napolitano, E. Schivardi, P. Fiore, M. Megna, G. Ianieri","doi":"10.4172/2161-0460.1000354","DOIUrl":"https://doi.org/10.4172/2161-0460.1000354","url":null,"abstract":"Introduction: Pisa syndrome (PS) is a lateral axial dystonia (LAD) characterized by contraction of the trunk muscles that results in a marked tonic lateral flexion of the thoraco-lumbar. PS has been described among symptoms of tardive neuroleptic dystonia, in patients with dementia treated with cholinesterase inhibitors, in patients with idiopathic primary dystonia, in patients with Parkinson’s disease (PD), Alzheimer’s disease and multiple system atrophy. Unlike most of motor PD symptoms, PS is not significantly improved by dopaminergic medications or surgery. In this study we demonstrated efficacy of botulinumtoxinA and physiotherapy in patients with PS post PD due to paraspinal muscles overactivity. Material and methods: ten patients evaluated until 6 months after treatment with 100U of IncobotulinumtoxinA (Xeomin®, Merz Pharma) in the paraspinal muscles and physiotherapy. We assessed baropodometric exam, goniometric measurement and VAS scale. Results: Data demonstrated statistical improvement (p<0,05) until 6 months after treatment in all evaluation examined. Conclusion: BotulinumtoxinA and physiotherapy treatments were well-tolerated and effective and could be considered a possible treatment in parkinsonian patients with LAD.","PeriodicalId":15012,"journal":{"name":"Journal of Alzheimers Disease & Parkinsonism","volume":"34 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91159106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Citicoline as Add-On Treatment in AlzheimerÃ¢ÂÂs Disease: Tips from theCiticholinage Study 胞胆碱作为AlzheimerÃⅱÂÂs疾病的附加治疗:来自胆碱化研究的提示

Journal of Alzheimers Disease & Parkinsonism Pub Date : 2017-07-24 DOI: 10.4172/2161-0460.1000353

P. Gareri, A. Castagna

引用次数: 1

Exploring the Genetic Architecture of Parkinson's Disease in a SouthernSpanish Population 在西班牙南部人群中探索帕金森病的遗传结构

Journal of Alzheimers Disease & Parkinsonism Pub Date : 2017-07-18 DOI: 10.4172/2161-0460.1000351

B. Sara, rés Ciga, C. Ruz, F. Barrero, F. Sevilla, Javier Pelegrina, M. Ramı́rez, F. Vives, R. Durán

引用次数: 0

AlzheimerÃ¢ÂÂs Disease Pathogenesis: The Denied Access Model AlzheimerÃ¢ÂÂs疾病发病机制:拒绝访问模型

Journal of Alzheimers Disease & Parkinsonism Pub Date : 2017-07-17 DOI: 10.4172/2161-0460.1000359

Wade N. Dauberman, Shaohua Xu

{"title":"AlzheimerÃ¢ÂÂs Disease Pathogenesis: The Denied Access Model","authors":"Wade N. Dauberman, Shaohua Xu","doi":"10.4172/2161-0460.1000359","DOIUrl":"https://doi.org/10.4172/2161-0460.1000359","url":null,"abstract":"Currently, AD has no cure and only treatments for the symptoms exist. Modern research still debates the toxic component of AD and the exact mechanism causing neurodegeneration. A hallmark of the disease is the production of the amyloid-beta (As) peptides and eventual self-assembly of these peptides into fibrils and extracellular As plaques. Both plaques and oligomers are proposed to be the direct cause of AD, but it remains unclear how the physical presence of these structures affect neuronal function and pathogenesis. Biomolecule aggregation is known to play a role in the pathogenesis of numerous diseases by restricting diffusion and bulk flow, and the same restriction could occur in the brain due to the dense amyloid plaques forming in the extracellular space. These plaques could prevent proper flow and diffusion of essential nutrients and prevent cellular waste removal by acting as extracellular channel blockades; however, limited models exist that address these issues. Alternative models and molecular tools need to be developed which focus on diffusion and bulk flow in relation to neural function and the physical presence of amyloid plaques. This review aims to evaluate the effect of the plaques on diffusion and bulk flow in relation to neural function in the brain.","PeriodicalId":15012,"journal":{"name":"Journal of Alzheimers Disease & Parkinsonism","volume":"10 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2017-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87013496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ophthalmic Artery Flow and Cognitive Performance in Patients withCarotid Artery Stenosis 颈动脉狭窄患者的眼动脉血流与认知能力

Journal of Alzheimers Disease & Parkinsonism Pub Date : 2017-07-14 DOI: 10.4172/2161-0460.1000350

Kuo-Lun Huang, M. Ho, Tsong-Hai Lee

{"title":"Ophthalmic Artery Flow and Cognitive Performance in Patients withCarotid Artery Stenosis","authors":"Kuo-Lun Huang, M. Ho, Tsong-Hai Lee","doi":"10.4172/2161-0460.1000350","DOIUrl":"https://doi.org/10.4172/2161-0460.1000350","url":null,"abstract":"The circle of Willis is regarded as the primary collaterals in patients with severe carotid artery stenosis (CAS), while the secondary collaterals from the reversed ophthalmic artery (OA) flow would be recruited when the primary collaterals are inadequate to maintain cerebral perfusion. Even though some reports suggest patients with reversed OA flow are more vulnerable to cerebral ischemic injury, whether reversed OA flow is adequate to maintain cognitive function or can be employed as a surrogate marker of cognitive impairment remains elusive. The purpose of this article is to review the dynamic behavior of collateral flow and to assess the relationship between OA hemodynamics, cerebral perfusion and cognitive performance in patients with CAS. There is evidence that the OA flow patterns behave dynamically according to the hemodynamic, metabolic, and neural demands. Patients with reversed OA flow have compensatory increased cerebral blood volume and timerelated perfusion parameters, while cerebral blood flow usually remains unchanged. Despite of the evidence having been scarce, the associations between hemodynamics of OA flow and cognitive performance have been observed in several recent studies. Furthermore, our previous study demonstrated a tendency for specific cognitive impairment observed in patients with reversed OA flow, depending on the side of reversed OA flow. However, the impacts of the OA flow patterns on cognition may be modified when the other pathogenic factors of stroke are taken into account. Concurrent application of multimodality neuroimaging findings about perfusion status and neural activities will greatly enhance our understanding of the relationships between the hemodynamics of OA flow and cognition.","PeriodicalId":15012,"journal":{"name":"Journal of Alzheimers Disease & Parkinsonism","volume":"40 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76158359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protein Gelation around Axons Inhibits Action Potential Propagation inNerve Fibers 轴突周围蛋白凝胶化抑制神经纤维内动作电位的传播

Journal of Alzheimers Disease & Parkinsonism Pub Date : 2017-07-13 DOI: 10.4172/2161-0460.1000349

Wade N. Dauberman, S. Breit, Shaohua Xu

引用次数: 0

Reliability of Post-mortem Biochemical Investigations after FatalTraumatic Brain Injury 致命性创伤性脑损伤后尸检生化检查的可靠性

Journal of Alzheimers Disease & Parkinsonism Pub Date : 2017-07-11 DOI: 10.4172/2161-0460.1000348

B. Ondruschka, M. Sieber, D. Pohlers, H. Franke, J. Dressler

{"title":"Reliability of Post-mortem Biochemical Investigations after FatalTraumatic Brain Injury","authors":"B. Ondruschka, M. Sieber, D. Pohlers, H. Franke, J. Dressler","doi":"10.4172/2161-0460.1000348","DOIUrl":"https://doi.org/10.4172/2161-0460.1000348","url":null,"abstract":"Objective: The aim was to test the reliability of former reported results of post-mortem laboratory investigations using cerebrospinal fluid (CSF) and serum levels of the biomarkers S100B and neuron specific enolase (NSE) to further evaluate the brain damage after fatal traumatic brain injuries. \u0000Methods: CSF and serum samples of 92 cases were collected during routine autopsies. The cases were divided into four groups regarding the causes of death in traumatic brain injury (TBI), isolated torso trauma, diffuse cerebral hypoxia and acute myocardial infarction. The samples were analysed using chemiluminescent immunoassays and the haemolytic index was quantified as internal control per sample (Roche Diagnostics). \u0000Results: There were significant differences in CSF values between TBI and all control cases (p<0.001), especially in comparison to fatal non-head injuries (p<0.05). Biochemical approaches in post-mortem serum are not suitable for both proteins. \u0000The marker levels increased with longer TBI survival time and peaked within the first three days after trauma. Former mentioned CSF cut-off values could be confirmed. \u0000Conclusion: Post-mortem investigations of CSF S100B and NSE can be declared a valuable tool in forensic practice since their levels indicate fatal TBI when empirically determined critical CSF values are reached.","PeriodicalId":15012,"journal":{"name":"Journal of Alzheimers Disease & Parkinsonism","volume":"74 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2017-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80353451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0